EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

Julie Schjødtz Hansen iD, Stefan Gustavsen iD, Homayoun Roshanisefat, Matthias Kant iD, Fin Biering-Sørensen, Claus Andersen, Anna Olsson, Helene Højsgaard Chow iD, Nasrin Asgari, Julie Richter Hansen, Helle Hvilsted Nielsen, Rikke Middelhede Hansen und 8 weitere

Pharmaceuticals · 28.07.2023 · 16 (8) · 1079

DOI: 10.3390/ph16081079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.07.2023. Verfasst von Julie Schjødtz Hansen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Aarhus University Hospital (AUH), 8200 Aarhus, Denmark. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Danish Ministry of Helath, The Danish Multiple Sclerosis Society, Bdr Hartmanns Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with multiple sclerosis (MS) and spinal cord injury (SCI) commonly sustain central neuropathic pain (NP) and spasticity. Despite a lack of consistent evidence, cannabis-based medicine (CBM) has been suggested as a supplement treatment. We aimed to investigate the effect of CBM on NP and spasticity in patients with MS or SCI. We performed a randomized, double-blinded, placebo-controlled trial in Denmark. Patients aged ≥18 years with NP (intensity >3, ≤9 on a numerical rating scale (NRS0-10) and/or spasticity (>3 on NRS0-10) were randomized to treatment consisting of either delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a combination of THC&CBD in maximum doses of 22.5 mg, 45 mg and 22.5/45 mg per day, respectively, or placebo. A baseline registration was performed before randomization. Treatment duration was six weeks followed by a one-week phaseout. Primary endpoints were the intensity of patient-reported NP and/or spasticity. Between February 2019 and December 2021, 134 patients were randomized (MS n = 119, SCI n = 15), where 32 were assigned to THC, 31 to CBD, 31 to THC&CBD, and 40 to placebo. No significant difference was found for: mean pain intensity (THC 0.42 (−0.54–1.38), CBD 0.45 (−0.47–1.38) and THC&CBD 0.16 (−0.75–1.08)), mean spasticity intensity (THC 0.24 (−0.67–1.45), CBD 0.46 (−0.74–1.65), and THC&CBD 0.10 (−1.18–1.39), secondary outcomes (patient global impression of change and quality of life), or any tertiary outcomes. We aimed to include 448 patients in the trial; however, due to COVID-19 and recruitment challenges, fewer were included. Nevertheless, in this four-arm parallel trial, no effect was found between placebo and active treatment with THC or CBD alone or in combination on NP or spasticity in patients with either MS or SCI. The trial was registered with the EU Clinical Trials Register EudraCT (2018-002315-98).

Schlagwörter

Stichwörter der Autor:innen

cannabidiol (CBD)cannabis-based medicine (CBM)delta-9-tetrahydrocannabinol (THC)neuropathic pain (NP)spasticity

Autor:innen und Institutionen

  • Department of Neurology, Aarhus University Hospital (AUH), 8200 Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark.
  • Danish Multiple Sclerosis Center (DMSC), Department of Neurology, Copenhagen University Hospital, Rigshospitalet, 2600 Glostrup, Denmark.
  • Department of Neurology, Naestved, Slagelse & Ringsted Hospitals, Region Zealand, 4200 Slagelse, Denmark.
  • Department of Neurology, Hospital of Southern Jutland, 6400 Soenderborg, Denmark.
  • Department of Neurology, Hospital South-West Jutland Esbjerg, 6700 Esbjerg, Denmark.

ORCID-Profile: Julie Schjødtz Hansen, Stefan Gustavsen, Matthias Kant, Helene Højsgaard Chow, Finn Sellebjerg, Peter Vestergaard Rasmussen

Förderung

  • The Danish Ministry of Helath
  • The Danish Multiple Sclerosis Society
  • Bdr Hartmanns Foundation
  • Karen A Tolstrup Foundation
  • Direktør Ejnar Jonasson kaldet Johnsen og hustrus mindelegat
  • Foundation for Reserach in Neurology
  • Lykfeldts Fond
  • Familien Hede Nielsens Fond

Zitieren

APA

Hansen, J. S., Gustavsen, S., Roshanisefat, H., Kant, M., Biering-Sørensen, F., Andersen, C., Olsson, A., Chow, H. H., Asgari, N., Hansen, J. R., Nielsen, H. H., Hansen, R. M., Petersen, T., Oturai, A. B., Sellebjerg, F., Sædder, E. A., Kasch, H., Rasmussen, P. V., Finnerup, N. B., & Svendsen, K. B. (2023). Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. Pharmaceuticals, 16(8), 1079. https://doi.org/10.3390/ph16081079

Vancouver

Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, et al. Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. Pharmaceuticals. 2023;16(8):1079. doi:10.3390/ph16081079

BibTeX
@article{Hansen2023,
  author = {Hansen, Julie Schjødtz and Gustavsen, Stefan and Roshanisefat, Homayoun and Kant, Matthias and Biering-Sørensen, Fin and Andersen, Claus and Olsson, Anna and Chow, Helene Højsgaard and Asgari, Nasrin and Hansen, Julie Richter and Nielsen, Helle Hvilsted and Hansen, Rikke Middelhede and Petersen, Thor and Oturai, Annette Bang and Sellebjerg, Finn and Sædder, Eva Aggerholm and Kasch, Helge and Rasmussen, Peter Vestergaard and Finnerup, Nanna Brix and Svendsen, Kristina Bacher},
  title = {Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {8},
  pages = {1079},
  doi = {10.3390/ph16081079}
}
Kostenlos starten →